Clinical Trials Logo
  1. Home
  2. Healthy Volunteers
  3. NCT06072144
  4. Details
NCT06072144 Clinical Trial

Validity and Reliability of the Smart Speed Device

Healthy Volunteers Clinical Trial

Official title:
Investigating the Reliability and Validity of the Smart Speed Device

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06072144
Other study ID # 2023/9
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 15, 2024
Est. completion date November 15, 2026

Study information
Verified date December 2023
Source Afyonkarahisar Health Sciences University
Contact Emel TASVURAN HORATA, PhD
Phone +905547759663
Email ethorata@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Smart Speed device developed at Zafer Teknopark in Turkey was developed to objectively assess reaction time. The aim of this study was to evaluate the validity and reliability of the Smart Speed device in comparison with BlazePod and Nelson Reaction Test.

Description:

The capacity to perceive, analyze, and react to a signal is referred to as reaction time. Reaction time is influenced by many factors such as visual and auditory factors. It is also influenced by individual factors such as age, gender, body mass index, attention and fatigue. Having reaction time within normal limits is very important for maintaining activities of daily living. BlazePod is a valid and reliable device for the assessment of reaction time. The Nelson Reaction test is also a valid and reliable test frequently used in the clinic for the assessment of reaction time due to its simple and rapid application. The Smart Speed device developed at Zafer Teknopark in Turkey was developed to objectively assess reaction time. The aim of this study was to evaluate the validity and reliability of the Smart Speed device in comparison with BlazePod and Nelson Reaction Test.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 46
Est. completion date November 15, 2026
Est. primary completion date November 15, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 24 Years
Eligibility Inclusion Criteria: - Without having systemic disease - To be able to speak Turkish language Exclusion Criteria: - Having a problem that affects physical performance

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Validity and reliability study
Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Afyonkarahisar Health Sciences University

Outcome
Type Measure Description Time frame Safety issue
Primary Assessment of reaction time To determine the validity and reliability of the Smart Speed device in assessing reaction time 15 minutes
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1